Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AVNSNYSE:ENOVNASDAQ:NVCRNYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVNSAvanos Medical$13.12+2.9%$13.19$11.84▼$25.36$606.54M1.13355,149 shs582,928 shsENOVEnovis$36.10+1.0%$35.15$29.32▼$52.76$2.06B1.79779,086 shs539,929 shsNVCRNovoCure$17.89+1.7%$17.70$14.17▼$34.13$1.99B0.731.16 million shs725,408 shsWRBYWarby Parker$17.71+0.8%$16.96$12.46▼$28.68$1.85B2.011.81 million shs2.01 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVNSAvanos Medical+2.87%+3.68%+8.76%-20.75%-34.52%ENOVEnovis+0.68%+9.24%+16.05%-17.73%-31.39%NVCRNovoCure+1.71%+2.93%+13.01%-20.42%-15.01%WRBYWarby Parker+0.73%+11.87%+24.45%-31.09%+12.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVNSAvanos Medical2.5727 of 5 stars0.03.00.00.02.72.52.5ENOVEnovis3.0662 of 5 stars3.42.00.00.03.11.71.9NVCRNovoCure3.6672 of 5 stars3.31.00.04.53.41.70.0WRBYWarby Parker3.7059 of 5 stars4.33.00.00.02.04.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVNSAvanos Medical 0.00N/AN/AN/AENOVEnovis 2.80Moderate Buy$58.0060.65% UpsideNVCRNovoCure 2.67Moderate Buy$32.8383.53% UpsideWRBYWarby Parker 2.69Moderate Buy$22.0024.23% UpsideCurrent Analyst Ratings BreakdownLatest AVNS, ENOV, NVCR, and WRBY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.005/13/2025WRBYWarby ParkerUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$23.00 ➝ $20.005/9/2025ENOVEnovisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.005/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $57.005/9/2025WRBYWarby ParkerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.005/9/2025WRBYWarby ParkerTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $22.005/1/2025WRBYWarby ParkerTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.004/30/2025WRBYWarby ParkerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Neutral$23.00 ➝ $17.004/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.004/22/2025WRBYWarby ParkerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$29.00 ➝ $18.004/17/2025WRBYWarby ParkerLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$27.00(Data available from 5/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVNSAvanos Medical$689.20M0.88$1.72 per share7.64$26.63 per share0.49ENOVEnovis$2.15B0.96$5.26 per share6.86$62.66 per share0.58NVCRNovoCure$621.71M3.21N/AN/A$3.39 per share5.28WRBYWarby Parker$795.09M2.33N/AN/A$3.08 per share5.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVNSAvanos Medical-$61.80M-$8.3738.587.58N/A2.30%4.70%3.46%7/30/2025 (Estimated)ENOVEnovis-$33.26M-$13.95N/A11.32N/A-5.95%4.39%2.80%N/ANVCRNovoCure-$207.04M-$1.51N/AN/AN/A-25.93%-41.48%-12.74%7/24/2025 (Estimated)WRBYWarby Parker-$63.20M-$0.12N/A177.09N/A-4.39%-8.26%-4.37%N/ALatest AVNS, ENOV, NVCR, and WRBY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/6/2025Q1 2025AVNSAvanos Medical$0.19$0.26+$0.07$0.14$161.75 million$167.50 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million2/27/2025Q4 2024NVCRNovoCure-$0.34-$0.61-$0.27-$0.61$161.30 million$161.27 million2/26/2025Q4 2024AVNSAvanos Medical$0.40$0.43+$0.03-$8.64$177.23 million$179.60 million2/26/2025Q4 2024ENOVEnovis$0.92$0.98+$0.06-$12.05$555.14 million$560.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVNSAvanos MedicalN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVNSAvanos Medical0.122.221.46ENOVEnovis0.402.271.12NVCRNovoCure0.271.491.44WRBYWarby ParkerN/A2.472.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVNSAvanos Medical95.17%ENOVEnovis98.45%NVCRNovoCure84.61%WRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipAVNSAvanos Medical2.64%ENOVEnovis2.70%NVCRNovoCure6.29%WRBYWarby Parker26.55%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVNSAvanos Medical4,04046.24 million44.15 millionOptionableENOVEnovis6,80057.12 million55.49 millionOptionableNVCRNovoCure1,320111.49 million101.40 millionOptionableWRBYWarby Parker3,030104.50 million74.67 millionOptionableAVNS, ENOV, NVCR, and WRBY HeadlinesRecent News About These CompaniesWarby Parker (NYSE:WRBY) Price Target Cut to $20.00 by Analysts at UBS GroupMay 16 at 3:59 AM | americanbankingnews.comNorthern Trust Corp Acquires 56,674 Shares of Warby Parker Inc. (NYSE:WRBY)May 16 at 3:46 AM | marketbeat.comWhich Is a Better Investment, The Buckle, Inc. or Warby Parker Inc. Stock?May 15 at 10:41 AM | aaii.comWhat Warby Parker’s Co-Founder Can Teach You About Breaking Into a Crowded IndustryMay 15 at 10:41 AM | inc.comBNP Paribas Financial Markets Buys Shares of 295,693 Warby Parker Inc. (NYSE:WRBY)May 15 at 4:01 AM | marketbeat.comWarby Parker (NYSE:WRBY) Shares Gap Up Following Analyst UpgradeMay 14 at 10:50 AM | marketbeat.comInvenomic Capital Management LP Sells 218,931 Shares of Warby Parker Inc. (NYSE:WRBY)May 14 at 6:08 AM | marketbeat.comAre Options Traders Betting on a Big Move in Warby Parker (WRBY) Stock?May 13, 2025 | msn.comD. E. Shaw & Co. Inc. Purchases 199,235 Shares of Warby Parker Inc. (NYSE:WRBY)May 13, 2025 | marketbeat.comWarby Parker (NYSE:WRBY) Shares Gap Up After Analyst UpgradeMay 13, 2025 | americanbankingnews.comTelsey Advisory Group Cuts Warby Parker (NYSE:WRBY) Price Target to $22.00May 12, 2025 | americanbankingnews.comHow some early feedback put Warby Parker on the path to successMay 11, 2025 | msn.comWarby Parker (NYSE:WRBY) Price Target Cut to $22.00 by Analysts at Telsey Advisory GroupMay 11, 2025 | marketbeat.comDriehaus Capital Management LLC Grows Stake in Warby Parker Inc. (NYSE:WRBY)May 11, 2025 | marketbeat.comAlgert Global LLC Reduces Stake in Warby Parker Inc. (NYSE:WRBY)May 11, 2025 | marketbeat.comWarby Parker (NYSE:WRBY) Price Target Raised to $20.00 at The Goldman Sachs GroupMay 11, 2025 | americanbankingnews.comWarby Parker Inc. (WRBY) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comEarnings call transcript: Warby Parker Q1 2025 results reveal revenue growthMay 10, 2025 | uk.investing.comWarby Parker Inc. (WRBY): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside PotentialMay 10, 2025 | finance.yahoo.comWarby Parker Inc (WRBY) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...May 9, 2025 | finance.yahoo.comDurable Capital Partners LP Has $218.32 Million Holdings in Warby Parker Inc. (NYSE:WRBY)May 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy Wells Fargo Is Buying $40 Billion of Its Own StockBy Gabriel Osorio-Mazilli | May 6, 2025View Why Wells Fargo Is Buying $40 Billion of Its Own StockChurchill Downs Stock: Could Tariff Fears Dampen Derby Gains?By Chris Markoch | April 26, 2025View Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?AVNS, ENOV, NVCR, and WRBY Company DescriptionsAvanos Medical NYSE:AVNS$13.12 +0.37 (+2.87%) Closing price 05/16/2025 03:59 PM EasternExtended Trading$13.12 +0.00 (+0.03%) As of 05/16/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.Enovis NYSE:ENOV$36.10 +0.37 (+1.05%) Closing price 05/16/2025 03:59 PM EasternExtended Trading$36.07 -0.03 (-0.09%) As of 05/16/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.NovoCure NASDAQ:NVCR$17.89 +0.30 (+1.71%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$17.89 0.00 (0.00%) As of 05/16/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Warby Parker NYSE:WRBY$17.71 +0.14 (+0.79%) Closing price 05/16/2025 03:59 PM EasternExtended Trading$17.58 -0.13 (-0.73%) As of 05/16/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
